Dianthus Therapeutics, Inc. /DE/ (DNTH) research
Dianthus Therapeutics, Inc. /DE/- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $98.35
- As of
Dianthus Therapeutics, Inc. /DE/ (DNTH): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
As of . Source: SEC EDGAR filings for DNTH. Method and limitations.
Share the DNTH intelligence card
See DNTH live in the terminal
Track DNTH's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live DNTH terminal, freeActive signals for DNTH
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 65% of DNTH (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8927% to DNTH (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +302% to DNTH (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 71% of DNTH (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +122% to DNTH (2026Q2)
FREE, NO ACCOUNT
Every signal on DNTH, as it fires
You are seeing 5 of 22 signals recorded on DNTH since 2026-05-26.
The five above all landed on 2026-09-06. The other 17 were recorded on 3 other days. 19 of the 22 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DNTH (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 252828108 · 2026Q2 | $95M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 252828108 · 2026Q2 | $10.5M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 252828108 · 2026Q2 | $9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 252828108 · 2026Q2 | $4.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DNTH
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
DNTH against its peers
DNTH's operating margin of -8739.3% ranks in the 9th percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | DNTH | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.0M USD | 227M USD | 9 | 16 |
| Operating margin | -8739.3% | -101.2% | 9 | 15 |
| Net margin | -7973.3% | -103.6% | 9 | 15 |
| Return on equity | -32.9% | -30.3% | 43 | 21 |
Peers (23): APLS, ERAS, CRSP, XENE, PTCT, LGND, DFTX, COGT, EWTX, TVTX, ACAD, ORKA, IOVA, CNTA, MANE, MIRM, SRRK, TLX, CGON, RLAY, BLTE, TNGX, RYTM. Left out: PBLS (no annual filing), BCHMY (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (DNTH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more DNTH signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to DNTHand get the insider, 13F, options, and confluence read in one view.